



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 31/568 ^(2006.01) **A61K 31/575** ^(2006.01)
A61K 31/56 ^(2006.01) **A61P 43/00** ^(2006.01)
A61P 1/16 ^(2006.01) **A61K 35/12** ^(2015.01)

(48) Corrigendum issued on:

05.01.2022 Bulletin 2022/01

(45) Date of publication and mention
of the grant of the patent:

01.12.2021 Bulletin 2021/48

(21) Application number: **19214560.5**

(22) Date of filing: **23.12.2014**

(54) **USE OF OXYGENATED CHOLESTEROL SULFATES (OCS) FOR TREATING ACUTE LIVER FAILURE**

VERWENDUNG VON OXYGENIERTEN CHOLESTERINSULFATEN (OCS) ZUR BEHANDLUNG
AKUTEM LEBERVERSAGEN

UTILISATIONS DE SULFATES DE CHOLESTÉROL OXYGÉNÉS (OCS) POUR TRAITER
L'INSUFFISANCE HÉPATIQUE AIGUE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **24.12.2013 US 201361920617 P**

(43) Date of publication of application:

22.04.2020 Bulletin 2020/17

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

14874617.5 / 3 086 793

(73) Proprietors:

- **Virginia Commonwealth University
Richmond, VA 23298 (US)**
- **The United States Government as Represented
by
The Department of Veterans Affairs
Washington, DC 20420 (US)**
- **Durect Corporation
Cupertino, CA 95014 (US)**

(72) Inventors:

- **REN, Shunlin
Richmond, VA Virginia 23249 (US)**
- **THEEUWES, Felix
Los Altos Hills, CA California 94022 (US)**
- **BROWN, James E.
Los Gatos, CA California 95032 (US)**
- **LIN, WeiQi
Emerald Hills, VA Virginia 94062 (US)**

(74) Representative: **J A Kemp LLP**

**80 Turnmill Street
London EC1M 5QU (GB)**

(56) References cited:

US-A1- 2012 264 816

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **Xu Leyuan ET AL:**
"25-Hydroxycholesterol-3-Sulfate Decreases Hepatic Steatosis and Inflammation in Mouse Models of Nonalcoholic Fatty Liver Disease by Down-Regulating Sterol Regulatory Element Binding Protein-1c", , 1 May 2011 (2011-05-01), XP055386695, Retrieved from the Internet: URL:[http://metcorner.gastro.org/article/S0016-5085\(11\)64071-7/pdf](http://metcorner.gastro.org/article/S0016-5085(11)64071-7/pdf) [retrieved on 2017-06-29]
- **L. XU ET AL: "5-Cholesten-3 ,25-Diol 3-Sulfate Decreases Lipid Accumulation in Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model"**, MOLECULAR PHARMACOLOGY, vol. 83, no. 3, 1 March 2013 (2013-03-01), pages 648-658, XP055230805, US ISSN: 0026-895X, DOI: 10.1124/mol.112.081505
- **DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 1998 (1998-07), BERNAL WILLIAM ET AL: "Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure"**, Database accession no. PREV199800371936 & **BERNAL WILLIAM ET AL: "Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure"**, JOURNAL OF HEPATOLOGY, vol. 29, no. 1, July 1998 (1998-07), pages 53-59, ISSN: 0168-8278

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification